Pfizer Inc. [NYSE: PFE] surged by $0.19 during the normal trading session on Friday and reaching a high of $51.95 during the day while it closed the day at $51.83. The company report on December 21, 2022 that Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
– Filings based on two Phase 3 trials demonstrating significant clinical remission versus placebo and safety profile consistent with previous studies.
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for etrasimod for individuals living with moderately-to-severely active ulcerative colitis (UC). The FDA’s decision is expected in the second half of 2023. The European Medicines Agency (EMA) has also accepted the Marketing Authorization Application (MAA) for etrasimod in the same patient population with the decision anticipated in the first half of 2024.
Pfizer Inc. stock has also gained 0.84% of its value over the past 7 days. However, PFE stock has inclined by 18.25% in the 3 months of the year. Over the past six months meanwhile, it has lost -0.10% and lost -12.23% year-on date.
The market cap for PFE stock reached $289.87 billion, with 5.61 billion shares outstanding and 5.61 billion shares in the current float. Compared to the average trading volume of 21.38M shares, PFE reached a trading volume of 9553617 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Pfizer Inc. [PFE]:
Goldman have made an estimate for Pfizer Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 13, 2022. While these analysts kept the previous recommendation, Credit Suisse raised their target price to Outperform. The new note on the price target was released on November 18, 2022, representing the official price target for Pfizer Inc. stock. Previously, the target price had yet another raise to $55, while SVB Leerink analysts kept a Mkt Perform rating on PFE stock.
The Average True Range (ATR) for Pfizer Inc. is set at 1.10, with the Price to Sales ratio for PFE stock in the period of the last 12 months amounting to 2.91. The Price to Book ratio for the last quarter was 3.14, with the Price to Cash per share for the same quarter was set at 6.46. Price to Free Cash Flow for PFE in the course of the last twelve months was 20.07 with Quick ratio for the last quarter at 1.40.
PFE stock trade performance evaluation
Pfizer Inc. [PFE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.84. With this latest performance, PFE shares gained by 6.10% in over the last four-week period, additionally sinking by -0.10% over the last 6 months – not to mention a drop of -11.72% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PFE stock in for the last two-week period is set at 57.87, with the RSI for the last a single of trading hit 55.17, and the three-weeks RSI is set at 58.69 for Pfizer Inc. [PFE]. The present Moving Average for the last 50 days of trading for this stock 48.58, while it was recorded at 51.56 for the last single week of trading, and 49.38 for the last 200 days.
Pfizer Inc. [PFE]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Pfizer Inc. [PFE] shares currently have an operating margin of +25.58 and a Gross Margin at +57.67. Pfizer Inc.’s Net Margin is presently recorded at +27.57.
Return on Equity for this stock inclined to 31.92, with Return on Assets sitting at 13.35.
Pfizer Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.60.
Earnings per share (EPS) analysis for Pfizer Inc. [PFE] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PFE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pfizer Inc. go to 0.79%.
Pfizer Inc. [PFE]: Insider Ownership positions
There are presently around $201,664 million, or 70.50% of PFE stock, in the hands of institutional investors. The top three institutional holders of PFE stocks are: VANGUARD GROUP INC with ownership of 493,584,761, which is approximately 1.052% of the company’s market cap and around 0.05% of the total institutional ownership; BLACKROCK INC., holding 432,615,438 shares of the stock with an approximate value of $22.42 billion in PFE stocks shares; and STATE STREET CORP, currently with $14.91 billion in PFE stock with ownership of nearly 0.138% of the company’s market capitalization.
Positions in Pfizer Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 1,492 institutional holders increased their position in Pfizer Inc. [NYSE:PFE] by around 104,574,369 shares. Additionally, 1,438 investors decreased positions by around 86,574,652 shares, while 357 investors held positions by with 3,699,716,021 shares. The mentioned changes placed institutional holdings at 3,890,865,042 shares, according to the latest SEC report filing. PFE stock had 132 new institutional investments in for a total of 15,364,937 shares, while 177 institutional investors sold positions of 7,051,394 shares during the same period.